Although TNF-α inhibitor treatment has shown improved therapeutic outcomes in various types of arthritis, the injection delivery of biological drugs will lead to increasing the risk of infection and decreasing patient dependency [49], which sets a barrier to the long-term delivery of TNF-α inhibitors. This evidence concerns the gene TNF and infection.